Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

Alexander M.M. Eggermont,Andrey Meshcheryakov,Victoria Atkinson,Christian U. Blank,Mario Mandalà,Georgina V. Long,Catherine Barrow,Anna Maria Di Giacomo,Rosalie Stephens,Shahneen Sandhu,Ragini R. Kudchadkar,Pablo L. Ortiz-Romero,Inge Marie Svane,Alexander C.J. van Akkooi,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

2021

9500Background: The phase 3 double-blind EORTC 1325/KEYNOTE-054 trial evaluated pembrolizumab (pembro) vs placebo in stage III cutaneous melanoma patients (pts) with complete resection of lymph nod...

Keywords:

Gastroenterology
Stage III cutaneous melanoma
Medicine
Internal medicine
complete resection
Pembrolizumab
Placebo
Lymph
Stage III melanoma

Correction
Source
Cite
Save

References

Citations